Showing results (401-410 of 629) with videos related to

Sort By:
Pageof 63
World Journal of Gastroenterology|July 15, 2005
Composition of common bile duct stones in Chinese patients during and after endoscopic sphincterotomyWei-Lun Tsai, Kwok-Hung Lai, Chiun-Ku Lin, et al.
The American Journal of the Medical Sciences|August 2, 2011
Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pyloriTsung-Hui Hu, Seng-Kee Chuah, Ping-I Hsu, et al.
Epidemiology (Sunnyvale, Calif.)|April 1, 2014
Matching on Race and Ethnicity in Case-Control Studies as a Means of Control for Population StratificationAnand P Chokkalingam, Melinda C Aldrich, Karen Bartley, et al.
Surgical Neurology International|December 28, 2020
Intracranial solitary fibrous tumor/hemangiopericytoma - A case seriesChi-Man Yip, Shu-Shong Hsu, Wei-Chuan Liao, et al.
Biomolecules|April 3, 2021
Eicosapentaenoic Acid Inhibits <i>KRAS</i> Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 PhosphorylationChing-Feng Chiu, Ming-I Hsu, Hsiu-Yen Yeh, et al.
Biochemical Pharmacology|January 9, 1992
Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cellsL S Kirschner, L M Greenberger, S I Hsu, et al.
Cancer Letters|February 4, 2024
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stressRam Sharma, Yung-Hsiao Chiang, Hsien-Chung Chen, et al.
Cell Reports|October 27, 2016
Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9Michael C Gundry, Lorenzo Brunetti, Angelique Lin, et al.
ACS Applied Materials & Interfaces|April 17, 2024
Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant GlioblastomaTsung-I Hsu, Yi-Ping Chen, Rong-Lin Zhang, et al.
Frontiers in Oncology|October 18, 2023
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancerPeter A Kaufman, Edward Neuberger, Naomi R M Schwartz, et al.
Pageof 63